• 1
    Mettlin CJ, Murphy GP, Ho R, Menck HR. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer. 1996; 77: 21622166.
  • 2
    Lu-Yao GL, Friedman M, Yao SL. Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J Urol. 1997; 157: 22192222.
  • 3
    Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial. A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. Cancer. 1995; 75: 19631968.
  • 4
    Wasson JH, Cushman CC, Bruskewitz RC, et al. A structured literature review of treatment for localized prostate cancer. Arch Fam Med. 1993; 2: 487493.
  • 5
    Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Committee on Cancer and the American Cancer Society. Cancer. 1998; 83: 16791684.
  • 6
    Klabunde CN, Potosky AL, Harlan LC, Kramer BS. Trends in black/white differences in treatment for nonmetastatic prostate cancer. Med Care. 1998; 36: 13371348.
  • 7
    Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001; 93: 18641871.
  • 8
    Shapira MM, McAuliffe TL, Nattinger AB. Treatment of localized prostate cancer in African-American compared with Caucasian men. Med Care. 1995; 33: 10791088.
  • 9
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373383.
  • 10
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613619.
  • 11
    World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death, based on the recommendations of the ninth revision conference, 1975. Geneva (Switzerland): World Health Organization, 1977.
  • 12
    Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998; 83: 11801188.
  • 13
    Desch CE, Penberthy L, Newschaffer CJ, et al. Factors that determine the treatment for local and regional prostate cancer. Med Care. 1996; 34: 152162.
  • 14
    Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol. 1996; 156: 127132.
  • 15
    Fowler JE, Terrell FL, Renfroe DL. Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol. 1996; 156: 17141718.
  • 16
    Bennett CL, Greenfield S, Aronow H, Ganz P, Vogelzang NJ, Elashoff RM. Patterns of care related to age of men with prostate cancer. Cancer. 1991; 67: 26332641.
  • 17
    Guralnik JM. Assessing the impact of comorbidity in the older population. Ann Epidemiol. 1996; 6: 376380.
  • 18
    Optenberg SA, Thompson IM, Friedrichs P, Wojcik B, Stein CR, Kramer B. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995; 274: 15991605.
  • 19
    Demark-Wahnefried W, Schildkraut JM, Iselin CE, et al. Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. Cancer. 1998; 83: 320330.
  • 20
    Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995; 13: 93100.
  • 21
    Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. JAMA. 1993; 269: 26332636.
  • 22
    ChenVW, HoweHL, WuXC, HotesJL, CorreaCN, editors. Cancer in North America, 1993–1997. Vol. 1: incidence. Springfield, IL: North American Association of Central Cancer Registries, 2000.
  • 23
    Bickell NA, Chassin MR. Determining the quality of breast cancer care: do tumor registries measure up? Ann Intern Med. 2000; 132: 705710.
  • 24
    Hillner BE, McDonald MK, Penberthy L, et al. Measuring standards of care for early breast cancer in an insured population. J Clin Oncol. 1997; 15: 14011408.
  • 25
    Bushhouse SA, Scharber WK. Cancer treatment: registry data versus claims data. Presented at the Annual Meeting of the North American Association of Central Cancer Registries, New Orleans, LA, April 2000.
  • 26
    Liu WL, Kasl S, Flannery JT, Lindo A, Dubrow R. The accuracy of prostate cancer staging in a population-based tumor registry and its impact on the black-white stage difference (Connecticut, United States). Cancer Causes Control. 1995; 6: 425430.